Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenetics of GLP-1 Response in Mexican-Americans With Prediabetes
NCT05119179Phase 4Recruiting
- Sponsor
- UTHealth Houston
- Start
- Nov 2021
- Primary completion
- Oct 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of semaglutide in prediabetes, sponsored by UTHealth Houston. Primary endpoints: Mean change in beta cell responsivity at 12 weeks, Insulin Sensitivity at 12 weeks and 15 more. Started Nov 2021; status: recruiting.
02
Drugs
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT05119179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05119179.